Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines

Antibody-targeted drugs and drug resistance—Challenges and solutions

(2015) LeeRon Shefet-Carasso et al.   DRUG RESISTANCE UPDATES

Advanced drug delivery nanosystems (aDDnSs): a mini-review

(2013) Costas Demetzos et al.   DRUG DELIVERY

Advanced drug delivery in motion

(2013) Enrico Mastrobattista   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Will nanomedicine deliver on its promise of changing therapeutics or remain an interesting and important research tool in cell biology and physiology?

(2013) Richard Kirsh et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Connecting drug delivery reality to smart materials design

(2013) David W. Grainger   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Towards more effective advanced drug delivery systems1

(2013) Daan J.A. Crommelin et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

SMART drug delivery systems: Back to the future vs. clinical reality

(2013) Twan Lammers   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Active drug targeting: Lessons learned and new things to consider

(2013) Khuloud T. Al-Jamal   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2013) Sara A. Hurvitz et al.   JOURNAL OF CLINICAL ONCOLOGY

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

(2013) Nahor Haddish-Berhane et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Antibody-drug conjugates

(2013) Alain Beck et al.   mAbs

Antibody–drug conjugates:

(2013) Stephen Ornes   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody–drug conjugates

(2013) Puja Sapra et al.   Expert Review of Clinical Pharmacology

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

(2012) Sandhya Girish et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

(2012) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

(2010) Teemu T. Junttila et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Nanomedicine–Nanoscale Drugs and Delivery Systems

(2010) Surya Singh   JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

(2008) Ezogelin Oflazoglu et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH